Page last updated: 2024-08-24

fluorexon and Uterine Cervical Neoplasms

fluorexon has been researched along with Uterine Cervical Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fan, YB; Li, HX; Liu, YZ; Wang, Z; Yi, ZC; Yin, Y; Zhuang, FY1
Banerjee, R; Huilgol, N; Preetha, A1

Other Studies

2 other study(ies) available for fluorexon and Uterine Cervical Neoplasms

ArticleYear
Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro.
    Cancer letters, 2006, Oct-08, Volume: 242, Issue:1

    Topics: Antineoplastic Agents; Connexin 43; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluoresceins; Gallic Acid; Gap Junctions; Gene Expression Regulation, Neoplastic; Glucosides; HeLa Cells; Humans; Hydrolyzable Tannins; In Vitro Techniques; Isoquinolines; Phenotype; Uterine Cervical Neoplasms

2006
Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes.
    The Journal of membrane biology, 2007, Volume: 219, Issue:1-3

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Membrane Permeability; Drug Combinations; Fatty Alcohols; Female; Fluoresceins; Fluorescent Dyes; Humans; In Vitro Techniques; Liposomes; Membrane Fluidity; Membranes, Artificial; Models, Biological; Paclitaxel; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Surface-Active Agents; Uterine Cervical Neoplasms

2007